NNC 0165 1562

Drug Profile

NNC 0165 1562

Alternative Names: NC01651562; NNC-01651562

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Obesity therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 01 Feb 2017 Novo Nordisk completes a phase I trial for Obesity in USA (NCT02568306)
  • 02 Oct 2015 Novo Nordisk plans a phase I trial for Obesity in USA (NCT02568306)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top